Abstract
Background: There is emerging data suggesting that the non-coding RNA (microRNA 193a or miR-193a) plays key roles in different types of cancers.
Objective: This review aims to investigate the functional significance of miR-193a in different cancers according to the information of literature.
Method: All the literature concerning miR-193a in cancer in PubMed are analysed.
Results: Several studies proved the association of miR-193a expression patterns with cancer’s stages, grades, response to the chemotherapy and even patient survival. Also, miR-193a can be used to differentiate some types of cancer. In cancer, miR-193a can act as a tumour suppressor gene or as an oncogene. Till now, several genetic factors (MAX, RXR α, XB130, P63, P73, AEG-1, HIFs, EGFR, Drosha, DGCR8, Dicer) and epigenetic factors (DNA methylation and long non-coding RNAs) were predicted to control miR-193a expression. They have fundamental effects on its biological behaviour in different types of cancers.
Conclusion: miR-193a has significant roles in cancer and can be targeted in the future for cancer therapy by better understanding of the factors that control its biological behaviour.
Keywords: miR-193a, cancer, chemotherapy, prognosis, mechanism, methylation.
Current Cancer Drug Targets
Title:Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Volume: 18 Issue: 7
Author(s): Afraa Mamoori, Vinod Gopalan and Alfred K-Y Lam*
Affiliation:
- Cancer Molecular Pathology, School of Medicine, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland,Australia
Keywords: miR-193a, cancer, chemotherapy, prognosis, mechanism, methylation.
Abstract: Background: There is emerging data suggesting that the non-coding RNA (microRNA 193a or miR-193a) plays key roles in different types of cancers.
Objective: This review aims to investigate the functional significance of miR-193a in different cancers according to the information of literature.
Method: All the literature concerning miR-193a in cancer in PubMed are analysed.
Results: Several studies proved the association of miR-193a expression patterns with cancer’s stages, grades, response to the chemotherapy and even patient survival. Also, miR-193a can be used to differentiate some types of cancer. In cancer, miR-193a can act as a tumour suppressor gene or as an oncogene. Till now, several genetic factors (MAX, RXR α, XB130, P63, P73, AEG-1, HIFs, EGFR, Drosha, DGCR8, Dicer) and epigenetic factors (DNA methylation and long non-coding RNAs) were predicted to control miR-193a expression. They have fundamental effects on its biological behaviour in different types of cancers.
Conclusion: miR-193a has significant roles in cancer and can be targeted in the future for cancer therapy by better understanding of the factors that control its biological behaviour.
Export Options
About this article
Cite this article as:
Mamoori Afraa , Gopalan Vinod and Lam K-Y Alfred *, Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression, Current Cancer Drug Targets 2018; 18 (7) . https://dx.doi.org/10.2174/1568009618666180308105727
DOI https://dx.doi.org/10.2174/1568009618666180308105727 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Cell Responses to Oxidative Stressors
Current Pharmaceutical Design Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology Haploidentical Stem Cell Transplantation in Childhood
Current Cancer Therapy Reviews From the Sea to Anticancer Therapy
Current Medicinal Chemistry Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery Antioxidant Supplements, Genetics and Chemotherapy Outcomes
Current Cancer Therapy Reviews Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
Reviews on Recent Clinical Trials Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery